# BEONE MEDICINES LTD. (ONC) FY2025 Annual Balance Sheet

- Company: BEONE MEDICINES LTD. (ONC)
- Period: As of 2025-12-31
- Filing: FY2025 10-K, filed 2026-02-26, accession number 0001628280-26-011946
- Page: https://plicit.ai/financials/onc/fy2025-annual-balance-sheet
- Chart image: https://plicit.ai/charts/onc-fy2025-annual-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 8,188,573,000 US dollars
- **Current assets**: 6,233,589,000 US dollars
- **Non-current assets**: 1,954,984,000 US dollars
- **Liabilities**: 3,827,379,000 US dollars
- **Current liabilities**: 1,828,830,000 US dollars
- **Non-current liabilities**: 1,998,549,000 US dollars
- **Equity**: 4,361,194,000 US dollars
- **Cash and cash equivalents**: 4,547,530,000 US dollars
- **Accounts receivable, net**: 865,080,000 US dollars
- **Inventories, net**: 608,227,000 US dollars
- **Prepaid expenses and other current assets**: 212,752,000 US dollars
- **Property, plant and equipment, net**: 1,641,678,000 US dollars
- **Operating lease right-of-use assets**: 148,184,000 US dollars
- **Other non-current assets**: 102,418,000 US dollars
- **Intangible assets, net**: 62,704,000 US dollars
- **Accrued expenses and other payables**: 1,109,120,000 US dollars
- **Accounts payable**: 479,035,000 US dollars
- **Research and development cost share liability, current portion**: 64,345,000 US dollars
- **Short-term debt**: 57,293,000 US dollars
- **Sale of future royalty liability, current portion**: 56,714,000 US dollars
- **Tax payable**: 41,625,000 US dollars
- **Operating lease liabilities, current portion**: 20,698,000 US dollars
- **Long-term debt**: 961,913,000 US dollars
- **Sale of future royalty liability, non-current portion**: 850,242,000 US dollars
- **Other long-term liabilities**: 80,245,000 US dollars
- **Deferred tax liabilities**: 53,209,000 US dollars
- **Operating lease liabilities, non-current portion**: 52,940,000 US dollars
- **Research and development cost share liability, non-current portion**: 0 US dollars
- **Additional paid-in capital**: 12,759,137,000 US dollars
- **Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,387,367,704 shares issued and 1,441,075,618 and 1,387,367,704 shares outstanding as of December 31, 2025 and 2024, respectively**: 144,000 US dollars
- **Accumulated deficit**: negative 8,319,903,000 US dollars
- **Accumulated other comprehensive loss**: negative 78,184,000 US dollars
- **Gross equity (calculated)**: 12,759,281,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.